URTI Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about URTI clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 29 trials

Recruiting
Phase 3

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria
Celldex Therapeutics1,370 enrolled15 locationsNCT07256392
Recruiting
Phase 2

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Novartis Pharmaceuticals44 enrolled17 locationsNCT06865651
Recruiting
Phase 3

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

Chronic Inducible UrticariaCold UrticariaSymptomatic Dermographism+1 more
Celldex Therapeutics240 enrolled72 locationsNCT07266402
Recruiting
Phase 3

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Chronic Spontaneous Urticaria (CSU)
Novartis Pharmaceuticals400 enrolled114 locationsNCT06868212
Recruiting

A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

Chronic Spontaneous Urticaria
Novartis Pharmaceuticals350 enrolled1 locationNCT07408219
Recruiting
Not Applicable

Circadian Rhythm Deregulation in Patients With CAPS

Cryopyrin Associated Periodic SyndromeFamilial Cold UrticariaMuckle-Wells Syndrome+1 more
Hospices Civils de Lyon30 enrolled6 locationsNCT06544018
Recruiting
Phase 2

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous UrticariaChronic Inducible Urticaria
Blueprint Medicines Corporation105 enrolled47 locationsNCT06931405
Recruiting

ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar

Chronic Spontaneous Urticaria (CSU)Allergic Asthma
Celltrion HealthCare France225 enrolled1 locationNCT07425639
Recruiting

A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria
Sanofi400 enrolled1 locationNCT07316114
Recruiting

Remibrutinib in Real-world Clinical Practice - a US Sub-study

Chronic Spontaneous Urticaria
Novartis Pharmaceuticals505 enrolled1 locationNCT07358780
Recruiting

Remibrutinib in Real-world Clinical Practice

Chronic Spontaneous Urticaria
Novartis Pharmaceuticals3,280 enrolled1 locationNCT07358364
Recruiting
Phase 1

A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria

Healthy SubjectsChronic Inducible UrticariaCold Urticaria+1 more
Granular Therapeutics Limited72 enrolled2 locationsNCT07181369
Recruiting

Vasculitis Pregnancy Registry

Behcet's DiseaseVasculitisCNS Vasculitis+12 more
University of Pennsylvania100 enrolled1 locationNCT02593565
Recruiting

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

VasculitisIgA VasculitisMicroscopic Polyangiitis (MPA)+7 more
Peter Merkel50 enrolled10 locationsNCT03004326
Recruiting
Phase 2

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria
Evommune, Inc.160 enrolled53 locationsNCT06873516
Recruiting

Deep Phenotyping of CIndU

Skin DiseasesAngio-Oedema and/or Urticaria
Centre for Human Drug Research, Netherlands40 enrolled3 locationsNCT07359430
Recruiting

Analysis of the Role of IgE Proteoforms in Health and Disease

AnaphylaxisHealthy ControlMastocytosis+6 more
KU Leuven200 enrolled1 locationNCT07328178
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes

Chronic Spontaneous Urticaria
Chengdu Suncadia Medicine Co., Ltd.66 enrolled1 locationNCT07230418
Recruiting
Not Applicable

Assessement of Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms

BronchiolitisURTI
Laboratoire de la Mer1,065 enrolled32 locationsNCT07262450
Recruiting
Phase 3

To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria
Taizhou Mabtech Pharmaceutical Co.,Ltd392 enrolled1 locationNCT06365879